Mammalian target of rapamycin inhibitors permit regulatory T cell reconstitution and inhibit experimental chronic graft-versus-host disease

Biology of Blood and Marrow Transplantation

Volumn 20, Issue 2, 2014, Pages 183-191

  Sugiyama, Haruko ^a   Maeda, Yoshinobu ^a   Nishimori, Hisakazu ^a   Yamasuji, Yoshiko ^a   Matsuoka, Ken ichi ^a   Fujii, Nobuharu ^a   Kondo, Eisei ^a   Shinagawa, Katsuji ^a   Tanaka, Takehiro ^a   Takeuchi, Kengo ^b   Teshima, Takanori ^c   Tanimoto, Mitsune ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b CANCER INSTITUTE   (Japan)

^c HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Chronic graft versus host disease (GVHD); Cyclosporine; Mammalian target of rapamycin (mTOR) inhibitor; Regulatory T cell

Indexed keywords

CYCLOSPORIN; EVEROLIMUS;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CD4+ T LYMPHOCYTE; CELL ISOLATION; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; DONOR; FEMALE; FLOW CYTOMETRY; HISTOPATHOLOGY; HOST; HYPOTHESIS; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; INOCULATION; MIXED LYMPHOCYTE REACTION; MOUSE; MYELOABLATIVE CONDITIONING; NONHUMAN; REGULATORY T LYMPHOCYTE; SPLEEN; STEM CELL EXPANSION; T LYMPHOCYTE; THYMUS; WILD TYPE;

CHRONIC GRAFT-VERSUS-HOST DISEASE (GVHD); CYCLOSPORINE; MAMMALIAN TARGET OF RAPAMYCIN (MTOR) INHIBITOR; REGULATORY T CELL;

ADOPTIVE TRANSFER; ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; GRAFT VS HOST DISEASE; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; T-LYMPHOCYTES, REGULATORY; TOR SERINE-THREONINE KINASES;

EID: 84893094206     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2013.11.018     Document Type: Article

References (46)

1. Teshima T., Wynn T.A., Soiffer R.J., et al. Chronic graft-versus-host disease: how can we release Prometheus?. Biol Blood Marrow Transplant 2008, 14:142-150.
2. Socie G., Stone J.V., Wingard J.R., et al. Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry. The New England journal of medicine 1999, 341:14-21.
3. Baker K.S., Gurney J.G., Ness K.K., et al. Late effects in survivors of chronic myeloid leukemia treated with hematopoietic cell transplantation: results from the Bone Marrow Transplant Survivor Study. Blood 2004, 104:1898-1906.
4. Deeg H.J., Lin D., Leisenring W., et al. Cyclosporine of cyclosporine plus methylprednisolone for prophylaxis of graft-versus-host disease: a prospective, randomized trial. Blood 1997, 89:3880-3887.
5. Storb R., Deeg H.J., Pepe M., et al. Graft-versus-host disease prevention by methotrexate combined with cyclosporin compared to methotrexate alone in patients given marrow grafts for severe aplastic anaemia: long-term follow-up of a controlled trial. Br J Haematol 1989, 72:567-572.
6. Kansu E., Gooley T., Flowers M.E., et al. Administration of cyclosporine for 24 months compared with 6 months for prevention of chronic graft-versus-host disease: a prospective randomized clinical trial. Blood 2001, 98:3868-3870.
7. Couriel D.R., Saliba R., Escalon M.P., et al. Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease. Br J Haematol 2005, 130:409-417.
8. Johnston L.J., Brown J., Shizuru J.A., et al. Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2005, 11:47-55.
9. Jurado M., Vallejo C., Perez-Simon J.A., et al. Sirolimus as part of immunosuppressive therapy for refractory chronic graft-versus-host disease. Biol Blood Marrow Transplant 2007, 13:701-706.
10. Jedlickova Z., Burlakova I., Bug G., et al. Therapy of sclerodermatous chronic graft-versus-host disease with mammalian target of rapamycin inhibitors. Biol Blood Marrow Transplant 2011, 17:657-663.
11. Cutler C, Logan BR, Nakamura R, etal. Tacrolimus/sirolimus vs. tacrolimus/methotrexate for graft-vs.-host disease prophylaxis after hla-matched, related donor hematopoietic stem cell transplantation: results of Blood and Marrow Transplant Clinical Trials Network Trial 0402. [ASH Annual Meeting Abstracts] Blood 2012;120:739.
12. Edinger M., Hoffmann P., Ermann J., et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nature Med 2003, 9:1144-1150.
13. Hoffmann P., Ermann J., Edinger M., et al. Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. JExp Med 2002, 196:389-399.
14. Taylor P.A., Lees C.J., Blazar B.R. The infusion of exvivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood 2002, 99:3493-3499.
15. Zeiser R., Leveson-Gower D.B., Zambricki E.A., et al. Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells. Blood 2008, 111:453-462.
16. Shin H.J., Baker J., Leveson-Gower D.B., et al. Rapamycin and IL-2 reduce lethal acute graft-versus-host disease associated with increased expansion of donor type CD4+CD25+Foxp3+ regulatory T cells. Blood 2011, 118:2342-2350.
17. Fontenot J.D., Rasmussen J.P., Gavin M.A., Rudensky A.Y. Afunction for interleukin 2 in Foxp3-expressing regulatory T cells. Nature Immunol 2005, 6:1142-1151.
18. D'Cruz L.M., Klein L. Development and function of agonist-induced CD25+Foxp3+ regulatory T cells in the absence of interleukin 2 signaling. Nature Immunol 2005, 6:1152-1159.
19. Setoguchi R., Hori S., Takahashi T., Sakaguchi S. Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. JExp Med 2005, 201:723-735.
20. Grusby M.J., Johnson R.S., Papaioannou V.E., Glimcher L.H. Depletion of CD4+ T cells in major histocompatibility complex class II-deficient mice. Science 1991, 253:1417-1420.
21. Anderson B.E., McNiff J.M., Matte C., et al. Recipient CD4+ T cells that survive irradiation regulate chronic graft-versus-host disease. Blood 2004, 104:1565-1573.
22. Reddy P., Maeda Y., Liu C., et al. Acrucial role for antigen-presenting cells and alloantigen expression in graft-versus-leukemia responses. Nature Med 2005, 11:1244-1249.
23. Sakoda Y., Hashimoto D., Asakura S., et al. Donor-derived thymic-dependent T cells cause chronic graft-versus-host disease. Blood 2007, 109:1756-1764.
24. Matsumoto Y., Hof A., Baumlin Y., et al. Differential effects of everolimus and cyclosporine A on intimal alpha-actin-positive cell dynamics of carotid allografts in mice. Transplantation 2004, 78:345-351.
25. Kaplan D.H., Anderson B.E., McNiff J.M., et al. Target antigens determine graft-versus-host disease phenotype. JImmunol 2004, 173:5467-5475.
26. Duffner U.A., Maeda Y., Cooke K.R., et al. Host dendritic cells alone are sufficient to initiate acute graft-versus-host disease. JImmunol 2004, 172:7393-7398.
27. Maeda Y., Tawara I., Teshima T., et al. Lymphopenia-induced proliferation of donor T cells reduces their capacity for causing acute graft-versus-host disease. Exp Hematol 2007, 35:274-286.
28. Coenen J.J., Koenen H.J., van Rijssen E., et al. Rapamycin, not cyclosporine, permits thymic generation and peripheral preservation of CD4+ CD25+ FoxP3+ T cells. Bone Marrow Transplant 2007, 39:537-545.
29. Miura Y., Thoburn C.J., Bright E.C., et al. Association of Foxp3 regulatory gene expression with graft-versus-host disease. Blood 2004, 104:2187-2193.
30. Rieger K., Loddenkemper C., Maul J., et al. Mucosal FOXP3+ regulatory T cells are numerically deficient in acute and chronic GvHD. Blood 2006, 107:1717-1723.
31. Zorn E., Kim H.T., Lee S.J., et al. Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease. Blood 2005, 106:2903-2911.
32. Matsuoka K., Kim H.T., McDonough S., et al. Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation. JClin Invest 2010, 120:1479-1493.
33. Bayer A.L., Jones M., Chirinos J., et al. Host CD4+CD25+ T cells can expand and comprise a major component of the Treg compartment after experimental HCT. Blood 2009, 113:733-743.
34. Zeiser R., Nguyen V.H., Beilhack A., et al. Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production. Blood 2006, 108:390-399.
35. Dunn C.J., Wagstaff A.J., Perry C.M., et al. Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral)1 in organ transplantation. Drugs 2001, 61:1957-2016.
36. Mantel P.Y., Ouaked N., Ruckert B., et al. Molecular mechanisms underlying FOXP3 induction in human T cells. JImmunol 2006, 176:3593-3602.
37. Abraham R.T., Wiederrecht G.J. Immunopharmacology of rapamycin. Annual review of immunology 1996, 14:483-510.
38. Blazar B.R., Taylor P.A., Panoskaltsis-Mortari A., Vallera D.A. Rapamycin inhibits the generation of graft-versus-host disease- and graft-versus-leukemia-causing T cells by interfering with the production of Th1 or Th1 cytotoxic cytokines. JImmunol 1998, 160:5355-5365.
39. Hess A.D., Fischer A.C., Horwitz L., et al. Characterization of peripheral autoregulatory mechanisms that prevent development of cyclosporin-induced syngeneic graft-versus-host disease. JImmunol 1994, 153:400-411.
40. Bucy R.P., Xu X.Y., Li J., Huang G. Cyclosporin A-induced autoimmune disease in mice. JImmunol 1993, 151:1039-1050.
41. Wu D.Y., Goldschneider I. Cyclosporin A-induced autologous graft-versus-host disease: a prototypical model of autoimmunity and active (dominant) tolerance coordinately induced by recent thymic emigrants. JImmunol 1999, 162:6926-6933.
42. Cutler C., Li S., Ho V.T., et al. Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation. Blood 2007, 109:3108-3114.
43. Alyea E.P., Li S., Kim H.T., et al. Sirolimus, tacrolimus, and low-dose methotrexate as graft-versus-host disease prophylaxis in related and unrelated donor reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2008, 14:920-926.
44. Rodriguez R., Nakamura R., Palmer J.M., et al. Aphase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens. Blood 2010, 115:1098-1105.
45. Rosenbeck L.L., Kiel P.J., Kalsekar I., et al. Prophylaxis with sirolimus and tacrolimus+/- antithymocyte globulin reduces the risk of acute graft-versus-host disease without an overall survival benefit following allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2011, 17:916-922.
46. Schleuning M., Judith D., Jedlickova Z., et al. Calcineurin inhibitor-free GVHD prophylaxis with sirolimus, mycophenolate mofetil and ATG in Allo-SCT for leukemia patients with high relapse risk: an observational cohort study. Bone Marrow Transplant 2009, 43:717-723.